Bli medlem
Bli medlem

Du är här

2016-11-15

Merus N.V.: Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antib

European Patent Office Dismisses Arguments by Regeneron

Favorable Rulings Further Strengthen IP Estate in Europe and Japan through
2029

UTRECHT, The Netherlands, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Merus N.V.
(NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, today announced that it received two
favorable rulings for its European patent EP 2147594 B1 (the "'594 patent")
by the Opposition Division of the European Patent Office (the "EPO") as well
by the Trial Board of the Japanese Patent Office for its Japanese counterpart
JP 5749161 (the "'161 patent"). Both patents cover Merus'
genetically-modified mice and their use to produce common light chain human
monoclonal antibodies.

"We are very pleased by these positive rulings for Merus' common light chain
mouse patents in Europe and Japan which we believe are a testament to the
strength of our intellectual property estate and provide us with sufficient
protection through 2029," said Ton Logtenberg, PhD, Chief Executive Officer
of Merus. "These favorable rulings reflect the unique attributes of our
proprietary Biclonics® bispecific antibody technology platform that we
believe has broad applicability in the development of novel therapeutics for
the treatment of cancer and other serious medical conditions."

In Europe, the Opposition Division of the EPO upheld without amendment the
'594 patent in oral proceedings held in The Hague on October 28, 2016. The
claims of the '594 patent cover methods of obtaining common light chain human
monoclonal antibodies from genetically-modified mice that comprise in their
genome a human rearranged immunoglobulin light chain variable region. In
Japan, the Trial Board of the Japanese Patent Office upheld the '161 patent
with minimal amendments. The claims of the '161 patent are similar to those
of the '594 patent.

Both the European Opposition Division and the Japanese Trial Board dismissed
arguments brought by Regeneron (NASDAQ:REGN) that the patent lacked novelty
and inventive step. In both territories, the decision is open to appeal.

About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal antibodies, such
as long half-life and low immunogenicity. Merus' lead bispecific antibody
candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in
Europe as a potential treatment for HER2-expressing solid tumors. Merus'
second bispecific antibody candidate, MCLA-117, is being developed in a Phase
1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also
has a pipeline of proprietary bispecific antibody candidates in preclinical
development, including MCLA-158, which is designed to bind to cancer stem
cells and is being developed as a potential treatment for colorectal cancer
and other solid tumors, and Biclonics® designed to bind to various
combinations of immunomodulatory molecules, including PD-1 and PD-L1.

Forward Looking Statement
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including without
limitation statements regarding the strength of our intellectual property
estate, the sufficiency of our protection of our intellectual property
estate, including when such protection will terminate, the broad
applicability of Biclonic® bispecific antibodies to cancer and other medical
conditions, and the treatment potential of our bispecific antibody
candidates.

These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including, but not
limited to, the following: we have incurred significant losses, are not
currently profitable and may never become profitable; our need for additional
funding, which may not be available and which may require us to restrict out
operations or require us to relinquish rights to our technologies or
bispecific antibody candidates; potential delays in regulatory approval,
which would impact the ability to commercialize our product candidates and
affect our ability to generate revenue; the unproven approach to therapeutic
intervention of our Biclonics® technology; potential difficulties in
validating and developing companion diagnostics, which could harm our
development strategy; our limited operating history; economic, political,
regulatory and other risks involved with international operations; exchange
rate fluctuations or abandonment of the euro currency; the lengthy and
expensive process of clinical drug development, which has an uncertain
outcome; the unpredictable nature of our early stage development efforts for
marketable drugs; potential adverse public reaction to the use of cancer
immunotherapies; potential delays in enrollment of patients, which could
affect the receipt of necessary regulatory approvals; our potential exposure
to costly and damaging liability claims; post-marketing restrictions or
withdrawal from the market; failure to obtain marketing approval
internationally; compliance with environmental, health, and safety laws and
regulations; anti-kickback, fraud, abuse, and other healthcare laws and
regulations exposing us to potential criminal sanctions; recently enacted or
future legislation; failure to compete successfully against other drug
companies; potential competition from other drug companies if we fail to
obtain orphan drug designation or maintain orphan drug exclusivity for our
products; the possibility that governmental authorities and health insurers
may not establish adequate reimbursement levels and pricing policies to
support our products; the potential failure of our product candidates to be
accepted on the market by the medical community; our lack of experience
selling, marketing and distributing products and our lack of internal
capability to do so; potential competition from biosimilars; our reliance on
third parties to conduct our clinical trials and the potential for those
third parties to not perform satisfactorily; our reliance on third parties to
manufacture our product candidates, which may delay, prevent or impair our
development and commercialization efforts; protection of our proprietary
technology; our patents being found invalid or unenforceable; potential
lawsuits for infringement of third-party intellectual property; adequate
protection of our trademarks; our potential failure to obtain extensions of
the terms of patents covering our products; potential difficulties protecting
our intellectual property rights in certain jurisdictions; changes in United
States patent law; protection of the confidentiality of our trade secrets;
claims asserting that we or our employees misappropriated a third-party's
intellectual property or otherwise claiming ownership of what we regard as
our intellectual property; compliance with patent regulations; potential
system failures; our ability to attract and retain key personnel; managing
our growth could result in difficulties; the price of our common stock may
fluctuate substantially; certain of our shareholders and members of our
management board own a majority of our outstanding shares and exercise
significant control over us; a significant portion of our total outstanding
shares are eligible to be sold into the market; provisions of our Articles of
Association or Dutch corporate law might deter favorable acquisition bids for
us or prevent a beneficial change of control; we may lose our foreign private
issuer status and incur significant expenses as a result; and unfavorable or
lacking analyst research or reports might cause the price of our common
shares to decline.

These and other important factors discussed under the caption "Risk Factors"
in our final prospectus filed with the Securities and Exchange Commission, or
SEC, on May 20, 2016 relating to our Registration Statement on Form F-1, and
our other reports filed with the SEC could cause actual results to differ
materially from those indicated by the forward-looking statements made in
this press release. Any such forward-looking statements represent
management's estimates as of the date of this press release. While we may
elect to update such forward-looking statements at some point in the future,
we disclaim any obligation to do so, even if subsequent events cause our
views to change. These forward-looking statements should not be relied upon
as representing our views as of any date subsequent to the date of this press
release.
Contacts:

Merus N.V.
Shelley Margetson - s.margetson@merus.nl
+31 (0)30 253 8800

Argot Partners
Kimberly Minarovich - kimberly@argotpartners.com
1-212-600-1902

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.